glp 1 vs gip 1 Two incretin hormones GLP-1 and GIP: Comparison of their actions in insulin secretion and β cell preservation Why does GLP‐1 agonist combined
Description
Why the Obesity GLP-1 Market is Growing
GI symptoms typically improve with continued use
There were no differences in older patients with or without comorbidities in either the LixiLan-O or LixiLan-L trials, except for slightly greater weight loss in patients with versus without comorbidities in the LixiLan-O trial (data on file)
Before it leads to harm to the body, weight loss becomes a crucial priority
Selection of the reported result
Consider: Will weight loss patients have to take these drugs forever
